Modulation of High Affinity Phenylalkylamine Binding Sites on Cultured Human Embryonal Vascular Smooth Muscle Cells

J DŘÍMAL

Institute of Experimental Pharmacology, Slovak Academy of Sciences, Dúbravská 9, 842 16 Bratislava

Abstract. Two phenylalkylamine Ca\(^{2+}\) channel ligands, (±)—[\(^{3}\)H]verapamil ((±)—[\(^{3}\)H]V) and (—)—[\(^{3}\)H]desmethoxyverapamil ((—)—[\(^{3}\)H]DV), were employed in whole cell binding assays to characterize the specific high affinity binding sites on Ca\(^{2+}\) channels, their cooperativity and modulations induced on cultured human embryonal vascular smooth muscle preparation (VSM) by 1) Beta-adrenergic stimulation of the cell, 2) exposure to high K\(^{+}\) concentration, 3) exposure to high concentration of Mg\(^{2+}\) ions, 4) the presence of a benzothiazepine Ca\(^{2+}\) channel antagonist and modulator d-cis-diltiazem, and 5) guanylylimidodiphosphate.

The total amounts of specific (±)—[\(^{3}\)H]V and (—)—[\(^{3}\)H]DV binding sites present on VSM cells increased significantly after beta-adrenergic receptor activation, following cell membrane depolarization induced by high concentrations of K\(^{+}\), in the presence of Ca\(^{2+}\) chelator Na\(_{3}\)EDTA, and after incubation of VSM cells with a benzothiazine- type Ca\(^{2+}\) channel blocker d-cis-diltiazem. A marked reduction of (—)—[\(^{3}\)H]DV binding was observed after permanent G-protein activation by a nonhydrolyzable analog of guanylylimidodiphosphate, after incubation of the cells with norepinephrine, and after incubation of VSM cells with millimolar concentration of Mg\(^{2+}\).

The results suggest the existence of multiple modulations of specific (—)—[\(^{3}\)H]DV binding sites on Ca\(^{2+}\) channel corresponding to the way of activation of the cell and also to the immediate “state” of the membrane bound Ca\(^{2+}\) channels present on VSM cells, the positive heterotropic interaction after beta-adrenergic stimulation, the homotropic positive allosteric interaction induced by d-cis-diltiazem and pure noncompetitive inhibition induced by guanylylimidodiphosphate. The presence of high concentrations of Mg\(^{2+}\) inhibited whereas the presence of Ca\(^{2+}\) chelator, of ethylenediamine- tetraacetic acid sodium salt, significantly increased the total number of specific high affinity (—)—[\(^{3}\)H]DV binding sites on VSM cells.
Key words: Calcium channel — Phenylalkylamine receptor — Calcium channel modulators — Human embryonal vascular smooth muscle cells — (−) − [³H]desmethoxyverapamil — (±) − [³H]verapamil — ligand binding

Introduction

Vascular smooth muscle (VSM) is presumably a therapeutic target of a class of compound known as Ca²⁺ antagonists. The Ca²⁺ channel protein binds Ca²⁺ channel drugs with high or low affinity to the resting, open, or inactivated state of the channel. There is evidence for phenylalkylamine (PAA), 1,4-dihydropyridine (DHP) and benzothiazepine (BTZ) receptors existing on Ca²⁺ channels as three distinct receptor sites that are reciprocally allosterically coupled (Ferry et al. 1984, Galizi et al. 1984, Gollet al. 1984, Glossmann et al. (1985). Ligand binding studies with skeletal muscle Ca²⁺ channels showed that PAAs may label specific binding sites that are inhibited by Ca²⁺ or other divalent cations (Schneider et al. 1991). Furthermore it has been shown that purified Ca²⁺ channel receptor protein binds PAAs with significantly lower affinity than does a membrane-bound receptor (Janis et al. 1987, Glossmann and Striessing 1988). Somewhat conflicting findings on PAA binding in purified Ca²⁺ channel proteins were recently explained by the existence of different states of Ca²⁺ channel attributed to the different conformation of the alpha subunit of the Ca²⁺ channel protein (Mikami et al. 1989). It has been proposed that association of PAA type Ca²⁺ channel ligand with the Ca²⁺ channel protein is possible only in physiologically relevant open state of the channel (Striessing et al. 1990). The cyclic version of the modulated Ca²⁺ receptor model assumes closed channels activating upon depolarization or stimulation with agonists and open transiently before passing into inactivated state (Jones 1991). Only the activation of Ca²⁺ channel is presumably directly affected by voltage, with the opening of the channel being faster and the closing slower at the depolarized voltages (Bean 1989).

The proposed allosteric model of modulated Ca²⁺ channel has recently been characterized also in vascular smooth muscle (Dřímal 1989, 1991, Dřímal et al. 1991). Our previous whole cell ligand binding studies have indicated that verapamil class drugs interact in an allosteric fashion with 1,4-DHP receptors on VSM cells to inhibit 1,4-DHP binding. The present study addresses these questions with pharmacologically modulated membrane-bound phenylalkylamine Ca²⁺ channel receptor of human embryonal vascular smooth muscle cell. Using this cell model we describe the general characteristics of specific binding of (−) − [³H]desmethoxyverapamil ((−) − [³H]DV) and [³H]verapamil ((±) − [³H]V) to native and pharmacologically pretreated human embryonal vascular smooth muscle cells.
Materials and Methods

Chemicals

(−)[3H]desmethoxyverapamil, specific activity 81.1 Ci/mmol (Knoll AG, Ludwigshafen, Germany); N-methyl-[3H]-verapamil-hydrochloride, specific activity 81 Ci/mmol (NEN Res. Prod., DuPont, Boston Ma., USA); BAYK8644 (Calbiochem); d-cis-diltiazem; (La-chema); guanylylimidodiphosphate (RBI); isoprenaline-hydrochloride (Fluka); phorbol 12-myristate-13-acetate (Sigma); noradrenalin (Sigma); Tris(hydroxymethyl)-aminomethane HCl (Serva); trisodium salt of ethylenediamine tetraacetic acid (Sodium Versenate, Riker Labs). Serum for cell cultures and other cell culture reagents were from Gibco (Grand Island, N.Y., USA).

Cell culture

VSM cells were originally obtained from human embryonal aorta (embryos 4–6 wk. of gestation). The VSM cells were grown in Dulbecco’s modified Eagle’s medium containing glucose and 10% heat inactivated (55 °C for 60 min) fetal bovine serum, penicillin G (50 i.u./ml), streptomycin-sulfate (50 /íl/ml) at 37°C in an athmosphere of 5% CO2 and 95% air. The cell line was maintained in the exponential growth phase by passaging every 4 days. Vascular smooth muscle cells had a characteristic spindleshape morphology and showed typical growth. The cell type used and the membrane bound receptors present on cells were characterized elsewhere (Dŕímal 1989, Dŕímal et al.1991). Experiments were performed on confluent cells in the eighth to fifteenth passage. The cells used for experimentation were plated in 35 ml plastic tissue culture dishes at a density $10^5$ cells/mm$^3$. After the VSM cells reached confluency they were washed with 5 ml of Tris-HCl — trisodium- ethylenediamine-tetraacetic acid buffer (0.54 mmol.l$^{-1}$ (sodium versenate) and 0.02 mol.l$^{-1}$ Tris-HCl, pH 7.4, at 37°C) and subsequently briefly with collagenase solution (0.1%), and centrifuged (at 250 $xg$ for 5 min) together with the cultivation medium without serum and glucose to collect detached cells. The cells were washed twice with the cultivation medium and then incubated for 60 min with the medium containing pharmacologically active substances. All experiments were carried out on confluent quiescent cells.

Cell viability

Cell counting was performed with Trypan blue according to Phillips (1973).

Radioligand binding to human VSM cells

At the end of 60 min incubation period both control and pretreated cells were scraped off the plates and harvested onto Whatman GF/C glass fiber filters. The cells were washed twice with 1.5 ml assay buffer (a mixture containing 80% of Dulbecco’s modified Eagle’s medium (without glucose and serum) with 20% of 50 mmol.l$^{-1}$ Tris/HCl, pH 7.51) and incubated for 60 min with (−)[3H]desmethoxyverapamil or (±)[3H]-verapamil (0.1 − −12 nmol.l$^{-1}$). After incubation the cells were washed twice with 3.0 ml of assay buffer and bound drug was separated from free drug by rapid filtration through GF/C glass microfibre filters followed by two consecutive buffer washes. The radioactivity bound on filters was collected in 10 ml scintillation cocktail LSD Spolana Neratovice and counted in a Rack Beta-Liquid Counter LKB Wallace Turku, Finnland at an efficiency of 65%.
Analysis of binding data was performed as described previously (Dřímal 1988, 1989). The specific binding was determined by subtracting binding in the presence of 0.1 μmol of unlabeled compound from values measured in the absence of the antagonist.

Experiments with guanylylimidodiphosphate were done on electropermeabilized cells. For purposes of permeabilization of the cell membrane, we used the method according to Rols et al. (1992) now widely applicable in studies with mammalian cells. The depolarisation conditions of cells were produced by incubating of cells in buffers containing high K⁺ concentrations (10, 20, 40 and 60 mmol.l⁻¹ K⁺).

Other determinations

Protein concentrations were measured by the method of Bradford (1976) using bovine serum albumin as standard. Data reported in the present study are mean values and the corresponding standard error of the mean. Non-linear regression analysis, Student's t-test for either paired or unpaired observations, and Statgraphic program package were used. Significance was considered to be present when \( P < 0.05 \).

Results

Cell viability: Confluent cultures of vascular smooth muscle cells derived from large arteries of human embryos contained a mixture of cells, endothelial cells and mostly adventitial fibroblasts. The cell responses to serum were dependent on the serum concentration in the cultivation medium, with the endothelial cell requirements being relatively large when compared to smooth muscle cells. A light micrograph showed the characteristic appearance of confluent smooth muscle cells: typical outgrowth (2–4 days of logarithmic growth), spindle-like cell form and more or less irregular shape.

The cells incubated in the presence of the pharmacologically active substances (in μmol.l⁻¹) guanylylimidodiphosphate (10.0), d-cis-diltiazem (0.1–1.0) and isoprenaline (0.1–20.0), or ( in mmol.l⁻¹) MgCl₂ (5.0–7.5) and trisodium salt of ethylenediamine tetraacetate (Sodium Versenate), (0.1–1.0) showed no evidence of lysis when compared by light microscopy with control cultures. Cell mortality, determined with the Trypan blue test was 3.2 ± 1.1% in both groups.

Characterization of \((-) - [³H]desmethoxyverapamil and \((\pm) - [³H]verapamil binding sites on native, polarized human embryonal vascular smooth muscle cells\)

Confluent human embryonal VSM cells were frozen for 2–3 days and thawed before use. It was found that VSM preparations can be stored for several days at –20°C without significant loss of growth in culture or loss of binding activity. Saturation analysis with two "open channel ligands" showed saturable binding to a homogenous population of high affinity binding sites. The tritiated Ca²⁺ channel antagonists of phenylalkylamine type used in the present study were \((-) - [³H]-DV\) and the more polyvalent, hydrophobic \((\pm) - [³H]verapamil, with more promiscuous
receptor binding affinity. As expected, (−)−[^3]HV labeled in polarized VSM cells significantly more binding sites with comparably lower affinity than did (−)−[^3]HDV, with $B_{\text{max}}$ being 745 ± 21 and 501 ± 21 fmol.mg⁻¹ and $K_D$ 12.2 ± 1.1 and 2.1 ± 0.18 respectively (Fig. 1).

![Graph of specific binding sites](image)

**Figure 1.** Characteristics of specific (±)−[^3]H]verapamil ((±)[^3]HV) and (−)−[^3]H]desmethoxyverapamil ((−)[^3]H]DV) binding sites identified on native cultured human embryonal vascular smooth muscle cells (n = 24). Note the significantly higher capacity and relatively low affinity of (±)[^3]H]verapamil binding sites on human embryonal smooth muscle cells. Asterisks indicate significant difference.
Characterization of (−)−[^3]H]desmethoxyverapamil binding to depolarized embryonal VSM cells

In depolarized VSM cells, shortly incubated in media containing 10, 20, 40 and 60 mmol.l⁻¹ K⁺, there was a marked and concentration dependent increase in specific binding of (−)−[^3]H]DV (+32 ± 7, +58 ± 11 and +59 ± 10%) with bath concentration of 20 mmol.l⁻¹ and a half maximal effect observed at approximately 40 mmol.l⁻¹ K⁺ in the medium (Fig. 2 and 3). The affinity of (−)−[^3]H]DV for receptor binding sites in these experiments was slightly higher with the numerical values of $K_D$ for the concentration of K⁺ producing half maximal increase in $B_{max}$ being $-18.9 + 5\%$, $(P < 0.05)$. Slight, but significant decrease in $K_D$ (−31.8 ± 7%) was seen with 60 mmol.l⁻¹ K⁺.

Pharmacology of (−)−[^3]H]desmethoxyverapamil specific binding sites in human VSM cells

In order to further explore the mechanisms of allosteric activation or inhibition of Ca²⁺ channel phenylalkylamine receptors in vascular smooth muscle cultured hu-
human embryonal cells were incubated with different pharmacological agents. Isoprenaline induced beta-adrenergic activation of VSM resulted in a significant increase in specific \((-\) - \[^3\text{H}\]DV binding \((+6 \pm 2\), \(+11 \pm 5\), \(+31 \pm 8\), \(+64 \pm 11\%\) with a half maximal effect at \(10.0 \mu\text{mol.l}^{-1}\) of isoprenaline and a slight but significant reduction in affinity of specific \((-\) - \[^3\text{H}\]DV binding sites on VSM cells (Figs. 2 and 3). The positive modulation of \((-\) - \[^3\text{H}\]DV specific binding induced by beta-adrenergic activation of VSM was significantly attenuated after short incubation of VSM in the presence of \(\text{Ca}^{2+}\) chelator of sodium-versenate.

On the contrary, incubation of native VSM cells with sodium versenate containing buffer significantly potentiated \((-\) - \[^3\text{H}\]DV specific binding to VSM cells. To characterize the regulatory effect of bivalent cations on \((-\) - \[^3\text{H}\]DV binding in VSM cells the cell line was incubated in the presence of high concentrations of \(\text{Mg}^{2+}\). In the presence of 5.0 and 7.5 mmol.l\(^{-1}\) \(\text{Mg}^{2+}\) in the media, specific \((-\) - \[^3\text{H}\]DV binding sites identified on VSM cells were significantly reduced without any significant change in apparent affinity. Direct G-protein activation with guanylylimidodiphosphate significantly reduced the specific binding of the phenylalkylamine \(\text{Ca}^{2+}\) channel antagonist. Incubation of VSM cells in buffer
with the Ca\(^{2+}\) chelator sodium-versenate attenuated the reduction in high affinity 
\((-\) — \(3^H\)DV specific binding induced by guanylylimidodiphosphate Phorbol-
myristate-acetate did not change the specific binding of \((-\) — \(3^H\)DV in VSM Incu-
bation of VSM cells with the higher of the two concentrations of benzothiazepine reduced affinity \((K_D = 150 \pm 9\%\)) and slightly but significantly increased the max-
imal number of specific binding sites identified on VSM cells. The presence of Ca\(^{2+}\) chelator and d-cis-diltiazem markedly increased affinity (a decrease by 70 9 ± 5% in
numerical values of \(K_D\)) without any significant change in \(B_{\text{max}}\). A combination of
high Mg\(^{2+}\) and d-cis-diltiazem in the incubation medium resulted in a significant
reduction in both binding parameters \((B_{\text{max}} = -69 8 \pm 7\%\) and \(K_D = -22 \pm 5\%\)
Upon increasing concentrations of noradrenaline \((0 1 - 5 0 \mu\text{mol}L^{-1})\) \(B_{\text{max}}\) was
reduced \((+6 \pm 1 2, +8 \pm 2, +12 \pm 4\) and \(+32 \pm 6\%\) and \(K_D\) of \((-\) — \(3^H\)DV increased
significantly

Discussion

These results are in agreement with the concept that phenylalkylamines bind selec-
tively to the open channel state in vascular smooth muscle (Sanquinetti and Kass
1984, Bean 1989) Furthermore, our results are in agreement with the view that
phenylalkylamines may bind within the intracellular opening of the transmembrane
pore of the ion channel (Stressig et al. 1990)

Previous studies have shown that \((-\) — \(3^H\)desmethoxyverapamil labeled mul-
tiple calcium channel receptors in brain and skeletal muscle (Reynolds et al. 1986),
and that guaninenucleotide binding proteins may modulate calcium channels in
cell membranes of equine portal vein smooth muscle (Rakotoaridsoa et al. 1991)
Our results obtained with the continuous cell line that expresses binding sites with
the characteristics of the receptors on Ca\(^{2+}\) channels have proven an extremely
useful tool in studying the regulation of membrane bound binding sites by events
associated with activation or inhibition of heterologic receptors on cells. Our data
obtained from experiments with exclusive labeling 1,4-DHP Ca\(^{2+}\) channel agonist
\((-\)—S—\([3^H]\)-BAYK 8644 and 1,4-DHP Ca\(^{2+}\) channel antagonist \((\pm)\) — \([3^H]\)PN 200—
110 binding sites on cultured vascular smooth muscle cells document the presence
of “open, presumably active” and “inactive” Ca\(^{2+}\) channels on native VSM cells in
a proportion of approximately 1 1, and modulations of 1,4-DHP binding sites in
the presence of phenylalkylamine Ca\(^{2+}\) channel blocker (Dšímal unpublished)
Consistently with this, the present study shows approximately 60% of phenylalkyl-
amine binding sites being labeled with \((-\) — \(3^H\)DV on quiescent VSM cells and a
further increase in \((-\) — \(3^H\)DV specific binding sites on pharmacologically activated
cells Kostyuk et al (1983) have postulated high affinity Ca\(^{2+}\), Mg\(^{2+}\) \((pK_{Ca} = 6 6\)
and \(pK_{Mg} = 4 2\) binding sites on the extracellular side of the Ca\(^{2+}\) channels, which
control the Ca\(^{2+}\) channel function In the light of these findings documented on
molluscan neurons, results obtained in our study suggest the existence of a regulatory site/s modulating the "open channel ligand" (—) – [3H]desmethoxyverapamil binding on cultured VSM cells, with the [3H]phenylalkylamine binding modulating the bivalent ion regulatory site and vice versa.

Taking the recently published concept of "cyclic version of Ca\(^{2+}\) channel" as a suitable model system of activation and inactivation response in polarized cells (Jones 1991) and the "open channel ligand" (—) – [3H]desmethoxyverapamil as a suitable tool for the identification of "active" Ca\(^{2+}\) channels on VSM cells, one can expect that upon depolarization the closed state of Ca\(^{2+}\) channel is destabilized transiently, before passing into inactivated state. This transient opening is the most probable explanation for the increased capacity of specific (—) – [3H]desmethoxyverapamil binding seen in the present study shortly after depolarization of VSM cells.

The findings of the positive modulation of (—) – [3H]desmethoxyverapamil specific binding, induced by beta-adrenergic stimulation of VSM, being markedly reduced in the presence of Ca\(^{2+}\) chelator in the incubation medium may mean that the presence of Ca\(^{2+}\) is a prerequisite for the appearance of positive modulation. The observation that positive modulation of (—) – [3H]desmethoxyverapamil binding, induced in the present study by benzothiazepine Ca\(^{2+}\) channel blocker, was markedly reduced by high Mg\(^{2+}\) may support the view that the presence of benzothiazepine, and possibly also bivalent cations in the channel, may produce a steric hindrance for the positive modulation of (—) – [3H]DV specific binding and/or this fact may indicate that the regulatory binding site(s) for Ca\(^{2+}\) and for benzothiazepines are presumably situated more proximally (superficially) than the specific binding site for (—) – [3H]desmethoxyverapamil. The negative modulatory effect of guanylylimidodiphosphate can be attributed to the loss of high affinity (—) – [3H]-desmethoxyverapamil binding as the result of permanent G-protein activation.

In conclusion, these findings suggest that (—) – [3H]phenylalkylamine specific binding sites identified on cultured human embryonal smooth muscle cells are modulated according to the state and immediate function of the Ca\(^{2+}\) channel receptor complex. The presence of high Mg\(^{2+}\) markedly reduces, and Ca\(^{2+}\) channel chelator EDTA in the cultivation medium increases, the specific binding. The benzothiazepine Ca\(^{2+}\) channel antagonist d-cis-diltiazem increased, and permanent G-protein activation with guanylylimidodiphosphate in electropermeabilized cells significantly reduced high affinity binding sites on VSM cells. Further data are needed to explain external factors imposed by other pharmacologically active agents on the intact cell in negative (inhibitory) modulation of Ca\(^{2+}\) channels. Such experiments are our current focus.
References


Dřímal J (1988) Heterogeneity of calcium channel agonist binding sites in the coronary artery Gen Physiol Biophys 7, 135–142

Dřímal J (1989) Regulation of beta-adrenergic receptors and calcium channel agonist binding sites in cultured human embryonal smooth muscle cells Gen Physiol Biophys 8, 341–350

Dřímal J (1991) Regulation of 1,4-dihydropyridine and betaadrenergic receptor sites in coronary artery smooth muscle Cell Signal 3, 225–232


Ferry D R, Goll A, Gadow C, Glossmann H (1984) (-)[3H]-Desmethoxyverapamil labeling of putative calcium channels in brain Autoradiographic distribution and allosteric coupling to 1,4-dihydropyridine and diltiazem binding sites Naunyn-Schmied Arch Pharmacol 327, 183–187


Reynolds I J, Snowmann A M, Snyder S H (1986) (-)[3H]-Desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes Differentiation by temperature and dihydropyridines J Pharmacol Exp Ther 237, 731–738

Final version accepted September 25, 1992